Ozempic and Mounjaro, originally diabetes medications, have exploded in popularity as powerful weight-loss injectables.

Popular drugs for weight loss are now being prescribed to kids as young as 12. It’s been nearly two years since the FDA approved their use in kids, but some are questioning if these drugs are safe for ...

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s ...

Thousands celebrate the rapid results of weight loss injections. But a new analysis reveals a harsh truth few are prepared ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...